<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00004153</url>
  </required_header>
  <id_info>
    <org_study_id>9308</org_study_id>
    <secondary_id>UCCRC-9308</secondary_id>
    <secondary_id>UCCRC-CTRC-9767</secondary_id>
    <secondary_id>NCI-G99-1620</secondary_id>
    <nct_id>NCT00004153</nct_id>
  </id_info>
  <brief_title>Detection of Melanoma Markers in Lymph Nodes or Peripheral Blood of Patients With Melanoma</brief_title>
  <official_title>Sensitive RT-PCR Analysis for Melanoma Markers From Lymph Nodes and Peripheral Blood in Patients With Melanoma</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Chicago</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Cancer Institute (NCI)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>University of Chicago</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      RATIONALE: Diagnostic procedures may improve the ability to detect the presence or recurrence
      of disease.

      PURPOSE: Diagnostic trial to detect melanoma markers in the lymph nodes or peripheral blood
      of patients who have melanoma.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      OBJECTIVES:

        -  Determine the feasibility of performing reverse transcriptase-polymerase chain reaction
           (RT-PCR) for five different tumor antigen genes using lymph node samples or peripheral
           blood from patients with melanoma.

        -  Determine the ability of PCR-positive lymph nodes or peripheral blood to predict relapse
           of disease in these patients.

        -  Determine the correlation of positive PCR results from peripheral blood with disease
           stage.

      OUTLINE: Lymph node biopsies or peripheral blood are obtained from patients. These specimens
      are examined by nested reverse transcriptase-polymerase chain reaction (RT-PCR) and analyzed
      for various tumor antigens.

      Patients may choose to be told the results of this testing, but the results do not influence
      or change the planned therapy. Brief counseling is required to discuss the results and their
      potential implications.

      Patients are followed for at least 2 years.

      PROJECTED ACCRUAL: A total of 30 patients for the lymph node portion and 80 patients (20 per
      stage of disease) for the peripheral blood portion will be accrued for this study within 3
      years.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>June 1998</start_date>
  <completion_date type="Actual">January 2005</completion_date>
  <primary_completion_date type="Actual">March 2004</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Diagnostic</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>To determine if there is a suggestion that PCR-positive lymph nodes predict relapse of disease</measure>
    <time_frame>3 years</time_frame>
  </primary_outcome>
  <enrollment type="Actual">106</enrollment>
  <condition>Melanoma (Skin)</condition>
  <intervention>
    <intervention_type>Genetic</intervention_type>
    <intervention_name>reverse transcriptase-polymerase chain reaction</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>sentinel lymph node biopsy</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        DISEASE CHARACTERISTICS:

          -  Clinically proven melanoma with indication to perform sentinel lymph node biopsy or
             elective lymph node dissection OR

          -  Histologically proven or diagnosis highly suspicious for melanoma

        PATIENT CHARACTERISTICS:

        Age:

          -  Any age

        Performance status:

          -  Not specified

        Life expectancy:

          -  Not specified

        Hematopoietic:

          -  Platelet count greater than 50,000/mm^3

          -  Hemoglobin greater than 7 g/dL

        Hepatic:

          -  PT less than 15 sec

          -  PTT less than 30 sec

        Renal:

          -  Not specified

        Other:

          -  No psychiatric illness that precludes compliance

          -  No other concurrent malignancy

        PRIOR CONCURRENT THERAPY:

        Biologic therapy

          -  Not specified

        Chemotherapy

          -  Not specified

        Endocrine therapy

          -  Not specified

        Radiotherapy

          -  Not specified

        Surgery

          -  Not specified
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Thomas F. Gajewski, MD, PhD</last_name>
    <role>Study Chair</role>
    <affiliation>University of Chicago</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University of Chicago Cancer Research Center</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60637</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>September 2013</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>December 10, 1999</study_first_submitted>
  <study_first_submitted_qc>January 26, 2003</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 27, 2003</study_first_posted>
  <last_update_submitted>September 4, 2013</last_update_submitted>
  <last_update_submitted_qc>September 4, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">September 5, 2013</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>stage I melanoma</keyword>
  <keyword>stage II melanoma</keyword>
  <keyword>stage III melanoma</keyword>
  <keyword>stage IV melanoma</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Melanoma</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

